Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
119
resultados
Última actualización
14/07/2026 [08:29:00]
Resultados 75 a 100 de 119
Resumen de: CN121532526A
The present disclosure provides methods and compositions for determining the risk of a patient unresponsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody, and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Resumen de: WO2026034527A1
Provided are a prophylactic or therapeutic agent for Crohn's disease, and a method for examining Crohn's disease. The prophylactic or therapeutic agent for Crohn's disease contains at least one selected from the group consisting of a RUNX2 inhibitor and a BHLHE40 inhibitor. The method for examining Crohn's disease includes (1) a step for detecting a protein and/or mRNA of at least one gene selected from the group consisting of RUNX2 and BHLHE40 in digestive tract-derived immune cells collected from a subject.
Resumen de: WO2024206308A2
Embodiments of the disclosure encompass methods and compositions for treating and/or identifying subjects having Inflammatory Bowel Disease (IBD). In certain embodiments, methods include measuring taxa occurrence frequencies in at least one microbiome sample from a subject suspected or having or being at risk for having IBD when certain taxa are enriched in the microbiome and/or when certain taxa are deficient in the microbiome, and particularly upon classification of their microbiome based on a taxa enrichment profile. In certain embodiments, an individual is determined to be a suitable donor for fecal microbiota transplant or is determined not to be a suitable donor for FMT based on classification of the taxa profile of their microbiome.
Resumen de: WO2024200594A1
Provided herein are methods for treating or preventing pouchitis comprising administering a SMAD7 antisense oligonucleotide or pharmaceutical formulations comprising the SMAD7 antisense oligonucleotide.
Resumen de: CN121499685A
The invention discloses a multi-index content determination method of hovenia acerba and rhizoma atractylodis bowel-relaxing granules, and belongs to the technical field of traditional Chinese medicine detection. The invention establishes a high performance liquid chromatography method for simultaneously determining nine components including caffeic acid, chicoric acid, naringin, naringin, hesperidin, neohesperidin, chrysophanol, aurantio-obtusin and atractylenolide I in a preparation, and the content of the components is calculated through a relative correction factor by taking caffeic acid as an internal reference by adopting a quantitative analysis of multi-components by single marker. According to the method, effective detection of the immature bitter orange medicinal material and the immature bitter orange base source is realized, and the immature bitter orange and the sweet orange base source of the traditional Chinese medicine immature bitter orange can be accurately distinguished, so that more comprehensive and accurate quality control of the traditional Chinese medicine is realized, and the stability and consistency of clinical efficacy of the traditional Chinese medicine are guaranteed.
Resumen de: EP4417707A2
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: CN121472476A
The invention discloses a citrus hybrid offspring authenticity identification method based on whole genome SNP (Single Nucleotide Polymorphism) analysis. According to the invention, a genome typing technology in a whole genome range is adopted, and a set of discrimination system capable of accurately identifying real hybrid offspring is established through high-density SNP (Single Nucleotide Polymorphism) marker analysis and an IBD (Identity by means of an algorithm. The method breaks through the limitation of a traditional method on hybrid filial generation identification, and provides reliable technical support for breeding practice.
Resumen de: WO2026027669A1
Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.
Resumen de: WO2026027676A1
Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.
Resumen de: US20260036584A1
This invention is directed to compositions and methods to detect and treat gastrointestinal diseases.
Resumen de: CN121445742A
本发明涉及双氢麦角胺在制备预防和/或治疗炎症性肠病的药物中的应用。本发明在炎症性肠病模型中验证得出一种全新的作用机制：炎症条件下TRIM25会介导LSD1的泛素化降解，引起肠上皮组织代谢紊乱加剧炎症。本发明通过预测TRIM25和LSD1结合的结构信息，使用虚拟药物筛选，筛到了双氢麦角胺小分子化合物，其可很好地占据TRIM25和LSD1互作的结合位点，抑制TRIM25和LSD1的互作，从而抑制LSD1的降解；在DSS诱导的小鼠结肠炎模型中，双氢麦角胺能缓解肠上皮因代谢紊乱造成的炎症激活，很好地缓解炎症性肠病的症状。上述过程作用机制明确，效果显著，实现了双氢麦角胺在治疗炎症性肠病方面的老药新用，具有较高的临床应用价值。
Resumen de: CN121454070A
本发明公开了琥珀酸对坏死性小肠结肠炎影响机制的研究方法，涉及生物医学研究技术领域；包括如下步骤：S1：动物模型建立：选择新生小鼠，随机分为4组；S2：干预周期：持续处理3‑5天，每日记录体重、存活率及存活状态；S3：样本采集：处死小鼠，取肠组织，分装用于不同检测；S4：多维度检测；S5：数据分析：整合表型、病理、分子数据，验证琥珀酸‑SUCNR1轴的功能。本发明构建了完整的研究琥珀酸‑SUCNR1轴在坏死性小肠结肠炎中作用机制的技术体系，通过动物模型构建、分子机制验证和病理评估的有机结合，形成了从现象观察到机制阐明的完整证据链，确保研究结论的可靠性。
Resumen de: CN121426979A
The invention belongs to the technical field of biological medicine, and particularly discloses cistanche polysaccharide as well as a preparation method and application thereof. The preparation method comprises the following steps: S1, washing, drying and crushing fresh cistanche, and removing impurities with absolute ethyl alcohol to obtain a reactant; s2, putting the reactant obtained in the step S1 into hot water for extraction, and adding absolute ethyl alcohol for precipitation after concentration to obtain crude polysaccharide; s3, adding a chloroform-n-butyl alcohol solution for deproteinization, and removing pigments by using macroporous resin; s4, chromatographic purification is conducted through a DEAE-52 cellulose column and a Sephadex G-100 gel column in sequence, polysaccharide components are collected, dialysis and freeze-drying are conducted, and the cistanche deserticola polysaccharide is obtained. The cistanche deserticola polysaccharide has a remarkable anti-inflammatory effect, can improve the richness and uniformity of intestinal flora, optimize flora balance and maintain the barrier function of the intestinal tract, and has a wide prospect in preparation of medicines for preventing or treating colitis.
Resumen de: WO2026024847A2
Affinity-based and activity-based probes (ABPs) described herein offer transformative resolutions to microbiome function. These ABPs target key metabolic pathways in the gut microbiome. The ABPs contain a binding group, a reactive group, and a. reporter group handle that allows for the addition of a "flexible" reporter group that can be easily swapped to enable multimodal fluorescence and proteomic measurements and isolation of live cells. The binding group, also called an affinity element or biorecognition element, mirrors monomeric and polymeric carbohydrates, sulfated and acetylated carbohydrates, and peptides to afford probe selectivity.
Resumen de: EP4684799A2
Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or integrins. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, inflammatory bowel syndrome, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
Resumen de: CN121410275A
The invention relates to a joint detection kit for predicting endoscopic response of inflammatory bowel disease in the technical field of medical examination, and solves the technical problem that the existing single biomarker is limited in detection sensitivity and specificity. Comprising an excrement calprotectin detection reagent and an excrement lactoferrin detection reagent, a monoclonal antibody sandwich ELISA method is adopted for calprotectin detection, and the detection range is 10-3000 mu g/g; the lactoferrin is detected by adopting a chemiluminescence immunoassay method, and the detection range is 5-500mu g/g. An endoscopic response prediction scoring model is established based on calprotectin concentration X and lactoferrin concentration Y: prediction score = alpha * ln (X + 1) + beta * ln (Y + 1) + clinical correction factor, alpha is 0.65-0.75, beta is 0.45-0.55, and the clinical correction factor integrates C-reactive protein, fecal occult blood and patient age. Compared with single detection, the sensitivity is improved to 85%-88%, and the specificity is improved to 83%-86%.
Resumen de: CN119433017A
The invention discloses an application of CCDC71L in diagnosis and treatment of radiation enteritis, and provides an application of a reagent for detecting the expression level of the CCDC71L in preparation of a product for diagnosing radiation enteritis and an application of an inhibitor of the CCDC71L in preparation of a medicine for treating radiation enteritis. The invention further provides a method for screening candidate drugs for treating or preventing radiation enteritis and a method for inhibiting the expression level of inflammatory factors in macrophages. Experiments prove that the CCDC71L can realize diagnosis of radiation enteritis, and discovers that inhibition of the CCDC71L can inhibit infiltration and polarization of macrophages so as to inhibit radiation-induced inflammatory reaction, and the CCDC71L marker provided by the invention provides a new idea for diagnosis and treatment of radiation enteritis, and has a wide application prospect.
Resumen de: CN121385324A
The invention belongs to the field of biological medicine, and particularly relates to application of soluble B7-H5 in preparation of a Crohn disease detection reagent. According to the invention, the level of soluble B7-H5 (sB7-H5) in serum of a patient suffering from Crohn's disease (CD) is deeply analyzed by using an ELISA (Enzyme-Linked Immunosorbent Assay) technology. Studies find that sB7-H5 in serum of a CD patient is remarkably and highly expressed and is positively correlated with a disease activity index (CDAI). Further experimental verification shows that blocking of B7-H5 can promote polarization of inflammatory macrophages. Based on the discoveries, the invention provides the application of the serum B7-H5 as the molecular marker of the Crohn's disease to development of products for detection, prognosis or treatment of the Crohn's disease. The molecular marker can be in a soluble B7-H5 gene or protein form. The invention also shows that the B7-H5 can be used as a potential target for developing the medicine for preventing and treating the Crohn disease, and has important clinical application value.
Resumen de: US2017266241A1
0001 This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.
Resumen de: US20260022426A1
Disclosed is a method for monitoring and evaluation of bowel health in premature newborns. The method involves collecting stool/fecal samples from premature newborns/babies and processing the sample using microbiomics, automated cell counting, flowcytometry, and RT PCR analysis using specific gene signature or RNA transcriptomics analysis to determine risk of necrotizing enterocolitis. The method allows evaluation and tracking of gut health without needing to draw a blood test and is a non-invasive method. The method diagnoses and prevents bowel inflammation, infection and necrotizing enterocolitis (NEC) that facilitates initiation of prompt therapy to limit morbidity and mortality in premature babies. The method facilitates early management of signs of NEC thereby helping to save lives of premature babies and infants having low birth weight.
Resumen de: WO2026020057A1
This disclosure provides for method for the diagnosis, prognosis and treatment of inflammatory bowel disease (IBD) and clinical subtypes of IBD in a subject by detecting the presence or level of one or more immune responses to self and microbial antigens in a sample from a subject.
Resumen de: WO2024189211A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Resumen de: CN121344178A
The invention provides an irritable bowel syndrome risk marker based on genomics. The risk marker comprises the following six pathogenic genes: CADM2, PHF2, PCLO, SHISA6, LRP1B and TANK. According to the invention, not only is the effect of the latest large-scale whole genome association research (GWAS) on the aspect of analyzing the genetic cause of the irritable bowel syndrome shown, but also five new genetic risk variation, potential unreported pathogenic genes and treatment targets of the irritable bowel syndrome are found; a new insight is provided for the cause of the irritable bowel syndrome, and a potential therapeutic intervention target is highlighted. The invention also provides an application based on the risk marker of the irritable bowel syndrome and a corresponding early screening kit.
Resumen de: WO2024240709A1
The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.
Nº publicación: CN121353785A 16/01/2026
Solicitante:
UNIV SHANGHAI
\u4E0A\u6D77\u5927\u5B66
Resumen de: CN121353785A
The invention discloses an inflammatory bowel disease classification and interpretable diagnosis method and system based on deep learning, an image acquisition module acquires image frames from colonoscope videos, and an image preprocessing module rejects low-quality images with high black pixel proportion and blurred images and executes color space normalization. The qualified image is sent to a double-stage segmentation model to obtain a polyp area mask image, the mask image is used for positioning an ROI image of the polyp area, the ROI image is input into a polyp classification model constructed based on a visual Transform structure, and a hyperplasia type or adenoma type classification result is obtained. According to the method, on the premise that extra cost input is not needed, the efficiency and accuracy of polyp recognition and grading in the colonoscope image are greatly improved, manual subjective errors are reduced, and the intelligent level and clinical practicability of early intestinal cancer screening are improved.
BOPI
Sede Electrónica
